At week @ , the between-group differences in the change from baseline in the ADAS-cog@ and DAD scores ( bapineuzumab group minus placebo group ) were -@ ( P = @ ) and -@ ( P = @ ) , respectively , in the carrier study ; the corresponding differences in the noncarrier study were -@ ( P = @ ) and @ ( P = @ ) with the @-mg-per-kilogram dose of bapineuzumab and @ ( P = @ ) and @ ( P = @ ) with the @-mg-per-kilogram dose .